# STINGRAY THERAPEUTICS, INC.: A Phase 1-2 clinical program for the teatment of Microsatellite Stable Colorectal Cancer with the combination of SR-8541A, Botensilimab, and Balstilimab

**Lab Budget Score:** 70/100

| Field | Value |
|---|---|
| Organization | STINGRAY THERAPEUTICS, INC. |
| Location | HOUSTON, TX |
| Project | A Phase 1-2 clinical program for the teatment of Microsatellite Stable Colorectal Cancer with the combination of SR-8541A, Botensilimab, and Balstilimab |
| Project number | 5R44CA278144-04 |
| Mechanism | R44 |
| Institute | National Cancer Institute |
| Award | $1,460,952 |
| Awarded | 2026-09-16 |
| Project period | 2025-08-14 to 2028-07-31 |
| UEI | XNADTMZYJMP5 |

## Why this score
- Award of $1M or more.
- Research or center grant: supplies, instruments and services budget.

Source: NIH RePORTER (newly awarded projects) (https://reporter.nih.gov/project-details/11393170). Last refreshed: 2026-11-03T18:16:24.961Z.
Award data comes from NIH RePORTER and may be revised by NIH. Organization-level only; investigator names and contacts are not included. Informational only.